Targeting ILK in solid tumors such as CRC could be effective in suppressing tumor growth via promoting TIS, enabling recruitment of anti-tumor immune cells into the TME thereby regulating SASP secretion (Figure 5). The gene discussed is ILK; the disease is colorectal carcinoma.